Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
14 01 2020
Historique:
received: 05 08 2019
accepted: 11 09 2019
pubmed: 22 9 2019
medline: 22 9 2020
entrez: 22 9 2019
Statut: ppublish

Résumé

Hematopoietic cell transplant (HCT) recipients are frequently infected with respiratory viruses (RVs) in the upper respiratory tract (URT), but the concordance between URT and lower respiratory tract (LRT) RV detection is not well characterized. Hematopoietic cell transplant candidates and recipients with respiratory symptoms and LRT and URT RV testing via multiplex PCR from 2009 to 2016 were included. Logistic regression models were used to analyze risk factors for LRT RV detection. Two-hundred thirty-five HCT candidates or recipients had URT and LRT RV testing within 3 days. Among 115 subjects (49%) positive for a RV, 37% (42 of 115) had discordant sample pairs. Forty percent (17 of 42) of discordant pairs were positive in the LRT but negative in the URT. Discordance was common for adenovirus (100%), metapneumovirus (44%), rhinovirus (34%), and parainfluenza virus type 3 (28%); respiratory syncytial virus was highly concordant (92%). Likelihood of LRT detection was increased with URT detection (oods ratio [OR] = 73.7; 95% confidence interval [CI], 26.7-204) and in cytomegalovirus-positive recipients (OR = 3.70; 95% CI, 1.30-10.0). High rates of discordance were observed for certain RVs. Bronchoalveolar lavage sampling may provide useful diagnostic information to guide management in symptomatic HCT candidates and recipients.

Sections du résumé

BACKGROUND
Hematopoietic cell transplant (HCT) recipients are frequently infected with respiratory viruses (RVs) in the upper respiratory tract (URT), but the concordance between URT and lower respiratory tract (LRT) RV detection is not well characterized.
METHODS
Hematopoietic cell transplant candidates and recipients with respiratory symptoms and LRT and URT RV testing via multiplex PCR from 2009 to 2016 were included. Logistic regression models were used to analyze risk factors for LRT RV detection.
RESULTS
Two-hundred thirty-five HCT candidates or recipients had URT and LRT RV testing within 3 days. Among 115 subjects (49%) positive for a RV, 37% (42 of 115) had discordant sample pairs. Forty percent (17 of 42) of discordant pairs were positive in the LRT but negative in the URT. Discordance was common for adenovirus (100%), metapneumovirus (44%), rhinovirus (34%), and parainfluenza virus type 3 (28%); respiratory syncytial virus was highly concordant (92%). Likelihood of LRT detection was increased with URT detection (oods ratio [OR] = 73.7; 95% confidence interval [CI], 26.7-204) and in cytomegalovirus-positive recipients (OR = 3.70; 95% CI, 1.30-10.0).
CONCLUSIONS
High rates of discordance were observed for certain RVs. Bronchoalveolar lavage sampling may provide useful diagnostic information to guide management in symptomatic HCT candidates and recipients.

Identifiants

pubmed: 31541573
pii: 5572451
doi: 10.1093/infdis/jiz470
pmc: PMC7107470
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-388

Subventions

Organisme : NHLBI NIH HHS
ID : K24 HL093294
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI118690
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI114844
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

J Clin Microbiol. 1996 Jul;34(7):1649-53
pubmed: 8784563
Biol Blood Marrow Transplant. 2013 Aug;19(8):1220-6
pubmed: 23680472
Clin Infect Dis. 2010 Jul 15;51(2):163-70
pubmed: 20524853
J Clin Virol. 2013 Dec;58(4):683-8
pubmed: 24125830
Transpl Infect Dis. 2009 Aug;11(4):298-303
pubmed: 19453994
Biol Blood Marrow Transplant. 2019 Jan;25(1):163-171
pubmed: 30149147
Blood. 2000 Apr 1;95(7):2240-5
pubmed: 10733491
Br J Haematol. 2008 Nov;143(4):455-67
pubmed: 18785968
J Infect Dis. 2010 May 1;201(9):1404-13
pubmed: 20350162
J Clin Microbiol. 2014 Nov;52(11):4020-2
pubmed: 25122864
J Infect Dis. 2017 Dec 5;216(10):1235-1244
pubmed: 28961971
J Clin Microbiol. 2015 Dec;53(12):3784-7
pubmed: 26378282
J Med Virol. 2009 Aug;81(8):1498-507
pubmed: 19551831
Am J Respir Crit Care Med. 2011 May 1;183(9):1262-79
pubmed: 21531955
Blood. 2009 Jun 4;113(23):5711-9
pubmed: 19299333
Clin Infect Dis. 2015 Jul 15;61(2):192-202
pubmed: 25847977
Respirology. 2017 Aug;22(6):1205-1211
pubmed: 28382762
Biol Blood Marrow Transplant. 2015 Oct;21(10):1802-7
pubmed: 26117558
J Immunol. 2018 Jun 15;200(12):3881-3889
pubmed: 29866770
Oncotarget. 2016 Aug 16;7(33):53930-53940
pubmed: 27340772
Blood. 2007 Sep 1;110(5):1681-8
pubmed: 17502457
Transpl Infect Dis. 2010 Aug 1;12(4):322-9
pubmed: 20487414
Appl Environ Microbiol. 2009 Mar;75(6):1559-65
pubmed: 19139223
Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14
pubmed: 20622030
Can Respir J. 2018 Apr 5;2018:2685723
pubmed: 29849830
Biol Blood Marrow Transplant. 2019 May;25(5):1011-1021
pubmed: 30537551
BMC Infect Dis. 2008 May 29;8:73
pubmed: 18510764

Auteurs

Jim Boonyaratanakornkit (J)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Meghana Vivek (M)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Hu Xie (H)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Steven A Pergam (SA)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Guang-Shing Cheng (GS)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Marco Mielcarek (M)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Joshua A Hill (JA)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Keith R Jerome (KR)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.

Ajit P Limaye (AP)

Department of Medicine, University of Washington, Seattle, Washington, USA.

Wendy Leisenring (W)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Michael J Boeckh (MJ)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Alpana Waghmare (A)

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Seattle Children's Hospital, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH